GeneDx Shares Rise as Company Prepares 27 Research Presentations for ASHG 2026
GeneDx Holdings Corp. (NASDAQ:WGS) announced that 27 of its scientific abstracts were accepted for presentation at the American Society of Human Genetics (ASHG) 2026 Annual Meeting. The company's stock rose 3.72% to $65.97 following the news.
The research highlights exome and genome sequencing applications across neurodevelopmental conditions, newborn screening, and AI-driven clinical interpretation. Key studies include findings from a clinical autism cohort of over 100,000 individuals and positive rate data from more than 19,000 infants in the GUARDIAN newborn screening trial.
Presentations will occur between October 21 and October 23, featuring three platform talks, three rapid-fire poster sessions, and a Reviewer's Choice poster awarded to the top 10% of submissions. Full study results remain under embargo until their scheduled session times at the conference.
Key points
- GeneDx had 27 scientific abstracts accepted for the American Society of Human Genetics 2026 Annual Meeting.
- The company's stock increased 3.72% to $65.97 following the research announcement.
- Featured studies evaluate genomic sequencing in autism cohorts exceeding 100,000 individuals and 19,000 newborn screening participants.
- Scheduled presentations include three platform talks, three rapid-fire poster talks, and one Reviewer's Choice poster.
- Detailed findings remain under embargo until their respective presentation dates between October 21 and October 23, 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
How many abstracts is GeneDx presenting at ASHG 2026?
GeneDx has 27 accepted scientific abstracts at the ASHG 2026 Annual Meeting, including three platform presentations, three rapid-fire poster talks, and one Reviewer's Choice poster.
What topics are covered in GeneDx's ASHG 2026 research?
Research focuses on machine learning for genomic interpretation, autism diagnostic yields in over 100,000 individuals, novel gene discovery, and newborn screening results from over 19,000 infants.
When will the full GeneDx ASHG 2026 study results be released?
All study results remain under embargo until their scheduled presentation or poster sessions at the conference between October 21 and October 23, 2026.